Scientific Reports (May 2017)

Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo

  • Remco van Dijk,
  • Sem J. Aronson,
  • Dirk R. de Waart,
  • Stan F. van de Graaf,
  • Suzanne Duijst,
  • Jurgen Seppen,
  • Ronald Oude Elferink,
  • Ulrich Beuers,
  • Piter J. Bosma

DOI
https://doi.org/10.1038/s41598-017-01602-w
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 9

Abstract

Read online

Abstract We aimed to identify potent biliverdin reductase (BVRA) inhibitors as a novel concept for the treatment of severe unconjugated hyperbilirubinemia. 1280 FDA-approved compounds were screened in vitro for their ability to inhibit human and rat BVRA activity and 26 compounds were identified as BVRA inhibitors. Montelukast and Disulfiram were selected as potentially clinically applicable drugs and tested to reduce serum unconjugated bilirubin (UCB) levels in the Ugt1a1-deficient rat, a model for chronic unconjugated hyperbilirubinemia. Oral administration of Disulfiram was toxic in the Ugt1a1-deficient rat (weight loss, transaminase elevation). Oral Montelukast administration led to low serum concentrations and did not alter serum UCB levels. Intraperitoneal injections of Montelukast resulted in concentrations up to 110 μmol/L in serum and 400 μmol/L in the liver. Still, serum UCB levels remained unaltered. This first study on biliverdin reductase inhibition as a novel concept for treatment of unconjugated hyperbilirubinemia identified putative in vitro BVRA inhibitors. Montelukast, the clinically most suitable inhibitor, did not result in reduction of serum UCB in the Ugt1a1-deficient rat. The proposed treatment strategy will not result in amelioration of severe unconjugated hyperbilirubinemia in humans without the identification or development of more potent BVRA inhibitors.